Description:

E1305 Nontarget Lesions Supplemental Form (RECIST) NCT00588770 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19F717BA-DF10-2BA5-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=19F717BA-DF10-2BA5-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 9/19/12
  2. 1/8/15
  3. 6/8/15
Uploaded on:

June 8, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

E1305 Nontarget Lesions Supplemental Form (RECIST) NCT00588770

INSTRUCTIONS: Complete this form only if more than 10 nontarget lesions were present at baseline. Submit original to ECOG Coordinating Center along with the appropriate RECIST Disease Evaluation Form (baseline or follow-up). Keep a copy for your files.

ECOG clinical trial administrative data
Reporting Period
Data amendment
On Treatment
On Treatment Report Period (since start of treatment)
Off Treatment
Off Treatment Report Period (since registration)
Nontarget Lesions
Site Code
Method of Evaluation
Follow-Up Status of Lesion (Choose one for each lesion. Leave blank if baseline.)
Cytology Result (For Site Code 04 effusion/ascites ONLY:)
Comments

Similar models